The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
The pharmacological basis of the short-duration response to dopaminergic stimulation in parkinsonism is not completely understood. Whereas it is generally assumed that the response reflects concurrent dopamine receptor occupancy, it is also possible that receptor activation triggers events that outlast the time that receptors are occupied by agonist. To distinguish between these two possibilities, we administered apomorphine, a mixed D1-D2 agonist with rapid equilibration between plasma and brain, to patients with parkinsonism. The clinical response to apomorphine injections lagged behind peak plasma concentrations and persisted beyond the time plasma concentrations following ineffective doses. We conclude that dopaminergic stimulation triggers effects that outlast the period of receptor occupancy by agonist. Understanding these steps may offer new pharmacological therapies for parkinsonism.
Gancher
S T
ST
Department of Neurology, Oregon Health Sciences University, Portland 97201-3098.
Woodward
W R
WR
Gliessman
P
P
Boucher
B
B
Nutt
J G
JG
D000368:Aged; D001058:Apomorphine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D007980:Levodopa / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*
D011954:Receptors, Dopamine; D007980:Levodopa; D001058:Apomorphine; D004298:Dopamine